Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Raises $23M in Public Offering of Shares

NEW YORK (GenomeWeb) – Trovagene said today it has closed a public offering of its common stock that brought in $23 million in gross proceeds. 

The company sold 5,111,110 shares of its shares, including 666,666 shares that were issued when the offering's underwriters exercised their overallotment option in full. The offering price was $4.50 per share, Trovagene said. The firm plans to use net proceeds for R&D, working capital, and other general corporate purposes. 

Piper Jaffray was the sole book-running manager on the offering. Janney Montgomery Scott, Maxim Group, and Cantor Fitzgerald acted as co-managers. 

Trovagene priced the offering last week, saying it anticipated $20 million in gross proceeds. The company had $31.2 million in cash and cash equivalents as of Sept. 30, 2014.  

Trovagene's shares rose 7 percent on the Nasdaq in afternoon trading to $5.17.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.